FDA durvalumab coverage for business development, investment, and market access teams
5 Notable Oncology FDA Approvals Granted in May: A B2B Analysis
May 2026 FDA Oncology Actions: 8 Approvals Reshape the Landscape
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
FDA Approves Durvalumab and BCG for High-Risk NMIBC
FDA Approves Imfinzi: Breakthrough for Stage III NSCLC Treatment